Background Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the
pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is …

Malignant pleural mesothelioma (MPM) is a deadly cancer primarily of the lung pleura,
strongly associated with asbestos exposure. According to the ESMO Clinical Practice …

Background: Available 2nd line chemotherapies for relapsed malignant pleural
mesothelioma (MPM) have limited activity. Results from early clinical trials-including the …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Background Although PD-1 inhibitors have demonstrated significant activity in MPM (Alley,
WCLC 2015; Kindler, WCLC 2016), not all patients benefit. About 1/3 of MPM have high PD …

Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor
prognosis, as current therapies are ineffective. Despite the increased understanding of the …

Introduction Dual immune checkpoint blockers regimen represents a standard first-line
therapy in unresectable pleural mesothelioma (PM). Novel combination strategies, including …

CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with
some differences in the efficacy of chemotherapy according to histology. The objective of this …

Abstract On March 28–29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy
Steering Committee, International Association for the Study of Lung Cancer, and …

Background Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate
and few therapeutic options. After platinum–pemetrexed combination, no further promising …